Perkins Capital Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Perkins Capital Management’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-13,479	Closed	-$802K	–	109
2020 Q3	$802K	Buy	+13,479	New	+$1.2M	0.74%	42
2020 Q1	$791K	Sell	13,522 -517	-4%	-$50.6K	0.96%	40
2019 Q4	$1.77M	Buy	14,039 +966	+7%	+$131K	1.59%	18
2019 Q3	$1.56M	Buy	13,073 +9,781	+297%	+$1.97M	1.35%	26
2019 Q2	$984K	Sell	3,292 -152	-4%	-$63.4K	0.69%	43
2019 Q1	$1.55M	Buy	3,444 +944	+38%	+$413K	1.02%	28
2018 Q4	$1.14M	Buy	2,500 +1,113	+80%	+$690K	0.89%	31
2018 Q3	$1.26M	Hold	1,387	–	–	0.76%	45
2018 Q2	$814K	Sell	1,387 -2	-0.1%	-$1.3K	0.58%	61
2018 Q1	$905K	Buy	+1,389	New	+$1.04M	0.81%	43

Other funds holding HTGM

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Perkins Capital Management's HTGM Position: Q4 2020 in Review

Perkins Capital Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2020, closing a stake of 13,479 shares — an estimated $802K sold.

Perkins Capital Management first reported a position in HTGM in Q1 2018 and held it in 10 quarters. The position peaked at $1.77M in Q4 2019. 23 funds tracked by Wall St. Rank hold HTGM as of Q4 2020.

Perkins Capital Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Perkins Capital Management sold 13,479 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2020, an estimated $802K.
Perkins Capital Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2018 and held it in 10 quarters.
Perkins Capital Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $1.77M in Q4 2019.
23 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2020.

Based on Perkins Capital Management's 13F filing for Q4 2020, filed 9 Feb 2021.